VersaBank

Management’s US$3 billion FY2027 funding target and US$1.75 incremental EPS estimate assume a 2.5% spread, rapid partner conversion, and substantial balance-sheet capacity; none is formal earnings guidance.

The expected lower SRP risk weighting is not approved. Management’s own timing for the preferred treatment is only an estimate around mid-2027, with interim insurance or tranche-transfer solutions also uncommitted.

Management repeatedly characterized Real-Time SRP as making traditional ABS obsolete, but analyst questioning did not establish signed pipeline volumes, retention economics, credit performance, or whether competitors can replicate the product.

Credit losses were a 0.02% recovery in the quarter, partly due to model updates and the branch-asset sale; the benign loss experience may not be representative as U.S. exposure scales.

Reported Q3 expenses included CAD 3.1 million of non-core costs and approximately CAD 2.3 million of other transitory costs, making the normalized earnings base difficult to assess.